Centre notifies new rules for drugs, clinical trials

Updated - March 26, 2019 10:53 pm IST

Published - March 26, 2019 09:59 pm IST - New Delhi

Representational image.

Representational image.

The Union Health Ministry has notified the Drugs and Clinical Trials Rules, 2019 with the government stating that the move is aimed at promoting clinical research in the country. The rules will apply to all new drugs, investigational new drugs for human use, clinical trials, bio-equivalence studies and ethics committees.

The highlights of the notification includes reduction in time for approving applications, which has now come down to 30 days for drugs manufactured in India and 90 days for those developed outside the country. “Also, in case of no communication from Drugs Controller General of India, the application will be deemed to have been approved,” the notification said.

As per the new rule the requirement of a local clinical trial may be waived for approval of a new drug if it is approved and marketed in any of the countries (EU, UK, Australia, Japan and US) specified by the Drugs Controller General with the approval of the government.

“The new rules will ensure patient safety and an ethics committee will monitor the trials and decide on the amount of compensation in cases of adverse events,” the ministry said.

Meanwhile, the Indian Society for Clinical Research (ISCR) said that the new Clinical Trial Rules are well balanced and will further the conduct of ethical and quality clinical trials in the country which, in turn, will benefit patients.

In a release issued on Tuesday, ISCR president Dr. Chirag Trivedi said: “The new rules protect the rights, safety and well-being of patients while ensuring a strong scientific base for the conduct of clinical trials.”

“We hope this will lead to more stability and growth in clinical research being done in India, which will ultimately ensure that our patients have access to faster and more effective treatment. India has the second largest population in the world and the highest disease burden but does less than 1.2% of global clinical trials,” he said.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.